On April 19, 2019, Mary Spellman, M.D., Chief Medical Officer of Menlo Therapeutics Inc. notified the company of her decision to leave her position with the company, effective May 31, 2019, to pursue other opportunities. Dr. Spellman will continue to serve as the Company's Chief Medical Officer through the Effective Date. Upon Dr. Spellman's departure, near-term responsibilities for the ongoing clinical trials will be assumed by Menlo's clinical staff, including Paul Kwon, M.D., the Company's current Chief Scientific Officer and former Chief Medical Officer.